Burzynski Research Institute IncOTC Pink - Current Information:BZYR
- LAST PRICE0.0341
- TODAY'S CHANGE (%)-0.0009 (-2.5714%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0350 / 0.0350
- Day Range
- 52 Week Range
- Volume82,814
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BZYR |
|---|---|---|
| 10:17 ET | 24714 | 0.039 |
| 10:37 ET | 12500 | 0.0394 |
| 10:42 ET | 15000 | 0.0496 |
| 11:49 ET | 18100 | 0.0341 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Burzynski Research Institute Inc | 4.6M | -5.2x | --- |
Evolutionary Genomics Inc | 4.7M | -2.0x | --- |
Tenax Therapeutics Inc | 4.5M | -1.0x | --- |
American Cryostem Corp | 4.4M | -2.3x | --- |
Windtree Therapeutics Inc | 4.3M | -0.1x | --- |
Vallon Pharmaceuticals Inc | 5.0M | -0.5x | --- |
Company Information
Burzynski Research Institute, Inc. is engaged in the research, production, marketing, promotion, and sale of certain medical chemical compounds. The chemical compounds are composed of growth-inhibiting peptides, amino acid derivatives, and organic acids, which are known under the trade name Antineoplastons. Antineoplastons are useful in the treatment of human cancer and is reviewing data from its Phase II clinical trials of Antineoplastons relating to the treatment of various cancers. Antineoplastons are found in the bodily fluids of humans and food. All Phase II clinical trials were for the treatment of a wide variety of cancers using only a combination of Antineoplastons A10 and AS2-1. Most of the trials involve the use of intravenous formulations of Antineoplastons; however, a few trials use oral formulations. The Company has not generated any operating revenue since its inception. The Company's clinical trials are conducted at the Burzynski Clinic.
Contact Information
- Headquarters
- 12000 Richmond AveHOUSTON, TX, United States 77082
- Phone
- 713-335-5697
- Fax
- 713-935-0649
Executives
- Chairman of the Board, President
- Stanislaw Burzynski
- Vice President - Clinical Trials
- Tomasz Janicki
- Treasurer, Secretary
- Patryk Goscianski
- Director
- Gregory Burzynski
- Director
- Carlton Hazlewood
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 131.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.51 |
EPS | $-0.01 |
Book Value | $0.00 |
P/E Ratio | -5.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
